Patients with bone metastases secondary to prostate cancer are predisposed to skeletal-related events (SREs), including spinal cord compression, pathological fracture, surgery to bone and radiotherapy to bone. The objective of this study was to document current patterns of healthcare utilization and costs of SREs in patients with prostate cancer and bone metastases. METHODS: This was a retrospective, observational study using the Thomson MedStat MarketScan Commercial Claims and Encounters database from September 2002 to June 2011. Study subjects included all persons with claims for prostate cancer and for bone metastases, and one or more claims for an SRE. Unique SRE episodes were identified based on a gap of at least 90 days without an SRE claim, and classified by treatment setting (inpatient or outpatient) and SRE type (spinal cord compression, pathological fracture, surgery to bone or radiotherapy). RESULTS: Of 3919 patients with prostate cancer and bone metastases, 2090 (53%) had one or more SRE episodes. Among 1237 patients who met all other criteria, there were 1623 SRE episodes over a mean (s.d.) follow-up of 16.1 (12.9) months. The percent of episodes that required inpatient treatment ranged from 14% (radiotherapy) to 82% (surgery to bone). On average, inpatient episodes with surgery to bone (n ¼ 36 episodes) were most costly (mean (s.e.) $88 838 ($11 830)/episode), whereas outpatient episodes with surgery to bone (n ¼ 8 episodes) were least costly (mean (s.e.) $4749 ($1690)/episode). Of the total SRE costs (mean (s.e.) $20 984 ($951)/episode), 41% were attributable to outpatient radiotherapy (n ¼ 1169 episodes), 23% to inpatient radiotherapy (n ¼ 184 episodes), and 19% to inpatient treatment of pathological fractures (n ¼ 101 episodes). CONCLUSIONS: In patients with prostate cancer and bone metastases, SREs are associated with high costs and hospitalizations. 1 The skeleton is the most common site of metastasis in men with advanced prostate cancer.
INTRODUCTION
Prostate cancer is one of the most common cancers in the United States, with an estimated 240 890 new cases and 33 720 deaths in 2011, and it is the second leading cause of cancer death in men behind lung cancer. 1 The skeleton is the most common site of metastasis in men with advanced prostate cancer. 2, 3 Median survival from diagnosis of bone metastases in men with prostate cancer is B3 years. 2, 4, 5 In men with bone-metastases of castrationresistant prostate cancer who have failed at least one hormonal therapy, median survival is B20 months. 6 Patients with bone metastases of prostate cancer are at risk of a variety of skeletalrelated events (SREs), such as pathological fractures, bone instability requiring surgery to the bone, radiation to the bone to control local tumor burden and manage pain, and spinal cord compression. These events can be associated with considerable morbidity, impaired health-related quality of life, reduced survival and increased healthcare costs. [7] [8] [9] Numerous studies have examined the impact of SREs on costs in patients with bone metastases secondary to solid tumors. [10] [11] [12] [13] [14] [15] [16] [17] [18] In an analysis of patients with prostate cancer, McKiernan et al. 17 estimated the expected costs of care directly attributable to SREs to be $9783 per patient. After matching on baseline characteristics, expected total medical-care costs were $20 484 greater in patients with SREs vs those without. Lage et al. 14 evaluated the costs of SREs in patients with prostate cancer and reported a mean cost of B$12 500 for treatment of SREs in the year following SRE diagnosis. Barlev et al. 10 recently examined the costs of hospitalizations for SRE in patients with bone metastasis secondary to prostate or breast cancer or with multiple myeloma. These authors reported that among patients with prostate cancer, the mean health plan payment per hospital admission was $59 788 for spinal cord compression, $22 390 for pathological fracture and $42 094 for surgery to the bone. Although these studies provide useful information on the costs of SREs in patients with bone metastases of solid tumors, they have some limitations. Although Barlev et al. 10 examined the costs of SREs treated in the inpatient setting, little is known regarding the relative magnitude of the costs of SREs treated on both an inpatient and an outpatient basis. Also, none of these studies have examined the costs of episodes of care for SREs. As defined in the literature, an episode of care (EOC) represents the period initiated by patient presentation with a diagnosis of a clinical condition and concluded when the condition is resolved. 19 EOC-based analyses have been used extensively to assess the costs of treatment of diseases such as diabetic foot ulcers, 20 abdominal pain 21 and low back pain. 22 As many patients experience more than one SRE, EOC-based cost analysis can be useful in understanding the economic impact of different types of SREs, and in informing estimates of the potential cost savings that might accrue as a result of interventions that may prevent them. 1 
MATERIALS AND METHODS

Study design and data source
A retrospective observational longitudinal cohort design was used. Data for this study were from the Thomson MedStat MarketScan Commercial Claims and Encounters database. This database contains information on the US health insurance claims of employees of large, self-insured corporations and their dependents, along with a few commercial health plans. The database is fully de-identified and compliant with the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Accordingly, institutional review board approval was not necessary. Data used in this study span the period from 1 September 2002 to 30 June 2011 ('study period').
Patient selection
Patients were included in the analysis if they met all of the following criteria: confirmed diagnosis of bone metastases (International Classification of Disease, 9th edition, Clinical Modification (ICD-9-CM) diagnosis codes 170.XX or 198.5X); confirmed diagnosis of prostate cancer (185.XX) before bone metastases diagnosis; and one or more SRE episodes (detailed algorithm is found in section below, titled as 'Identification of SREs'). For the purpose of this study, a patient was considered to have a 'confirmed' diagnosis if the patient had one or more inpatient facility claims with the diagnosis code or codes of interest listed as the primary diagnosis on the claim, or two or more medical claims on different days and no more than 6 months apart, with the same diagnosis code or codes of interest listed in any diagnosis field on the claims. This approach of identifying confirmed diagnoses was used to improve the specificity of diagnoses based in ICD-9-CM diagnosis codes on health insurance claims. These codes may lack specificity if listed on claims for services provided to rule out certain diseases or as working diagnoses while clinical diagnoses are confirmed by pathological or other means.
The 'index date' was defined as the date with the first confirmed diagnosis of bone metastases. The 6-month period before the index date was designated the 'pre-index period'; the period from the index date to the end of continuous enrollment was designated the 'follow-up period'. Patients o18 years of age on the index date, with gender specified as female, o6 months of continuous enrollment before the index date, a diagnosis of primary cancer other than prostate cancer before the index date, or with invalid cost data were excluded. Because diagnoses codes for primary cancer may sometimes be used for metastatic disease, patients were assumed to have other primary cancer only if they did not also have a corresponding claim for metastasis to the same site. For example, patients with claims with a diagnosis of primary liver neoplasm (ICD-9-CM 155.XX) as well as claims with diagnosis of metastasis to the liver (197.0X, 197.1X, 197.2X, and 197.3X) were not considered to have 'other primary cancer'. Conversely, those with claims with diagnoses of primary liver neoplasm but without a claim for metastasis to the liver were assumed to have 'other primary cancer'. Codes for identification of primary and secondary malignancies by site are listed in Supplementary Appendix A.
Patient characteristics
For each patient, baseline demographic characteristics and comorbidities were assessed as of the index date, including calendar year, age, region, plan type and Deyo's version of the Charlson Comorbidity Index. 23 Preindex healthcare utilization and costs also were measured including: the number of outpatient pharmacy claims or procedures for chemotherapy, systemic corticosteroids and intravenous bisphosphonates; the number of outpatient pharmacy claims (that is, prescriptions) for opioids and oral bisphosphonates; and the number of claims for inpatient hospitalizations, emergency department visits, home healthcare visits, hospice care, skilled nursing facility care, physician office visits, hospital outpatient visits, laboratory tests and other care. In counting these services, multiple claims occurring on the same day were counted once, except for outpatient prescriptions. Also tallied were the costs of inpatient hospitalizations, emergency department visits, home healthcare visits, hospice care, skilled nursing facility care, physician office visits, hospital outpatient visits, laboratory tests and other healthcare services. Costs were approximated based on paid amounts (total gross payment after applying pricing guidelines such as fee schedules and discounts, but before applying deductibles, coinsurance, copayments and coordination of benefit).
Identification of SREs
For each patient, the follow-up period was scanned to identify all medical claims indicative of an SRE (spinal cord compression, pathological fracture, surgery to bone or radiotherapy). Diagnosis and procedure codes used to identify SREs are listed in Supplementary Appendix B. The codes used to identify SREs were based on coding algorithms used in prior studies, [11] [12] [13] 17 supplemented with discussion with clinical and coding experts. When there was uncertainty with respect to the inclusion of codes for the identification of SREs, the coding algorithm was designed to be as specific as possible to avoid the inclusion of events that were not actually SREs. Regarding the identification of pathological fractures, there are two different sets of ICD-9-CM codes for fractures. Pathological or spontaneous fractures are classified in the musculoskeletal and connective tissue chapter of ICD-9-CM (ICD-9-CM 733.1X), whereas traumatic fractures are classified in the injury and poisonings chapter of ICD-9-CM (ICD-9-CM 800-824). Because pathological or spontaneous fractures may be associated with trivial trauma such as a minor fall, many such fractures may be incorrectly coded as traumatic fractures. For the purpose of this study, pathological fracture was therefore identified based on confirmed diagnoses of pathological fracture (ICD-9-CM 733.1X) or a confirmed diagnosis of traumatic fracture (ICD-9-CM 800-824) (see 'Patient selection' section for the definition of confirmed diagnosis). Claims with codes for traumatic fracture (ICD-9-CM 800-824) were only included, however, if there were no concurrent claims with codes suggesting accident (excluding accident codes for 'falls on the same level') or trauma. 'Concurrent claims' were defined as claims occurring during the 2-week period ending with the claim for the fracture. When identifying a confirmed diagnosis of fracture, all diagnosis codes for fractures to the same site were considered as confirmatory. When identifying surgery to bone, claims with concurrent claims suggesting accident (excluding falls on the same level) or significant trauma also were excluded. Because there are no body site modifiers for procedure codes for radiotherapy, claims for radiotherapy procedures were considered only if there was a concurrent claim with a diagnosis code for bone metastasis, spinal cord compression, bone pain (ICD-9-CM 733.90) or pathological fracture.
For each patient with at least one SRE claim during the follow-up period, SRE episodes were identified using a gap of 90 days or more without an outpatient claim or an inpatient admission for an SRE. Gaps were defined based on the number of days without SRE claims starting with the last SRE encounter (Figure 1 ). The choice of the 90-day gap was based on the observation that the mean daily cost of SRE-related care by time since the first SRE claim declined rapidly between 1 and 3 months after the first SRE claim and leveled off shortly thereafter.
Each SRE episode was then classified into mutually exclusive categories. SREs include both diagnoses (spinal cord compression and pathological fracture) as well as procedures (surgery to bone and radiotherapy). These procedures may be used in the treatment of the diagnosed condition(s) (for example, surgery to bone may be used for a pathological fracture). Spinal cord compression can present as an oncologic emergency, Figure 1 . Example for identifying SRE episodes with 90-day gap. Gaps were defined based on the number of days without SRE claims starting with the last SRE claim. PF, pathological fracture; RT, radiotherapy; SB, surgery to bone; SCC, spinal cord compression; SRE, skeletal-related event.
potentially leading to severe and permanent neurological damage including paresis or paralysis, loss of control of bladder and/or bowel function, loss of independence, reduced quality of life, and reduced survival. [24] [25] [26] [27] Accordingly, in defining mutually exclusive categories, we used a hierarchy in which the diagnoses of spinal cord compression and pathological fracture were at the top, and surgery to bone and radiotherapy were at the bottom. This yielded the following hierarchy for identifying mutually exclusive categories of SRE episodes based on evidence of confirmed diagnoses or procedures: spinal cord compression; pathological fracture without spinal cord compression; surgery to bone without spinal cord compression and without pathological fracture; and radiotherapy without any other types of SRE claims. Episodes were further classified as 'inpatient' or 'outpatient' based on the presence during the episode of one or more inpatient hospital claims with any SRE.
Outcome measures and analyses
For each SRE episode, all the claims during the episode were scanned and classified as SRE-related or non-SRE-related according to ICD-9-CM diagnosis codes and procedure codes listed in Supplementary Appendix B. For each SRE episode, all the SRE-related costs (payments) were tallied and adjusted to calendar year 2010 US dollars. 28 The number and percentages of SRE episodes by type of SRE, treatment setting, and SRE claims identified during the episode, and the mean (s.d.) SRE-related cost per episode by type of SRE and treatment setting were calculated. All analyses were conducted using SAS Proprietary Software, Release 9.2.3 (SAS Institute, Cary, NC, USA).
RESULTS
Of 3919 patients with bone metastases and prostate cancer identified in the dataset, 2090 patients (53%) had at least one SRE. Of these, 1237 patients met all other criteria (Table 1) .
Mean (s.d.) age was 58.8 (4.6) years, 42% of patients resided in the South, followed by North Central (29%), West (16%) and Northeast (12%), and the majority had preferred provider organization (PPO) (61%), followed by health maintenance organization (HMO) (13%) plan types ( Table 2 ). The mean (s.d.) Charlson index during the pre-index period was 3.5 (2.6), consistent with advanced prostate cancer. The mean (s.d.) duration of follow-up was 16.1 (12.9) months.
There were 1623 SRE episodes identified among 1237 patients. Among spinal cord compression episodes (n ¼ 40), B75% of the episodes included claims for radiotherapy, while 25% included claims for pathological fracture (Table 3) . Among pathological fracture episodes (n ¼ 186), B51% of the e4pisodes included claims for radiotherapy, while 26% included claims for surgery to bone, and 38% included pathological fracture claims alone. Among surgery to bone episodes (n ¼ 44), 52% included claims for radiotherapy. Almost all episodes with claims for radiotherapy (90%) were classified as radiotherapy episodes. Values are numbers of claims. Except for medications, claims on the same day are counted once. HMO, health maintenance organization; PPO, preferred provider organization.
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Twenty one percent of all SREs required inpatient treatment. Only 14% of radiotherapy episodes required inpatient treatment, whereas 82% of surgery to bone episodes required inpatient treatment.
The mean (s.e.) cost per episode was $54 751 ($3526) for inpatient episodes and $11 768 ($481) for outpatient episodes (Figure 2 ). On average, inpatient surgery to bone episodes were most costly with mean (s.e.) cost per episode of $88 838 ($11 830), followed by inpatient pathological fracture episodes with mean (s.e.) cost per episode of $64 125 ($8089). Outpatient episodes with surgery to bone were least costly with mean (s.e.) cost per episode of $4749 ($1690).
DISCUSSION
This was a retrospective, observational study using health insurance claims data to document patterns of healthcare utilization and costs associated with SRE episodes in patients with prostate cancer and bone metastases. Results of this analysis suggest that in patients with prostate cancer and bone metastases, SREs episodes are associated with high costs and hospitalizations.
This study differs from prior studies of the costs of SREs in that an EOC approach was used for estimating the costs of SREs. EOC analysis is appropriate for analyzing the economic burden of clinical events when their treatments involve a series of separate but related healthcare services. By using an EOC approach, a more complete picture of the costs of events can be obtained. Future health insurance claims-based studies on the costs of SREs, as well as potential other events such as adverse events of treatment of disease progression in cancer patients, should explore the use of EOC analysis.
Use of and EOC approach, however, requires a rule for defining each episode. Our decision to use a 90-day gap to define SRE episodes was based on the observation that the mean daily costs of SRE-related care declined rapidly from 30 to 90 days post SRE, and leveled off shortly thereafter. Some prior clinical trials of bone modifying drugs have used a 21-day window to calculate cumulative incidence of SREs 6 or skeletal morbidity rate. 29 However, the use of gaps rather than windows to identify unique SRE episodes is consistent with traditional EOC analyses.
It is instructive to compare results of this study with those reported by Barlev et al., 10 which also used the MedStat MarketScan databases to evaluate the costs of inpatient SRE episodes in patients with bone metastasis secondary to prostate or breast cancer. Although the mean cost per hospitalization for spinal cord compression in prostate cancer patients reported by Barlev et al. 10 ($59 788) is similar to the mean cost per inpatient episode for spinal cord compression from our study ($54 458), the mean costs per hospitalization for pathological fracture and surgery to bone reported by Barlev et al. ($22 390 and $42 094, respectively) are considerably lower than the mean costs per inpatient episode for pathological fracture and surgery to bone reported here ($64 125 and $88 838, respectively). This difference may be a consequence of a number of factors. First, inpatient episodes in this study include follow-up outpatient care, whereas Barlev et al. 10 considered only the cost of hospitalization. Second, this study used wider sets of codes to identify pathological fracture and surgery to bone. Third, Barlev et al. 10 used data from both commercial plans and Medicare. This study focused on commercial plans only because of the possibility that some care received by Medicare patients may not be captured in the MedStat database. Limitations of this study should be noted. This study used administrative claims data that may be subject to data coding limitations and data entry error. Also, diagnostic and procedure codes on claims may have limited sensitivity and specificity for clinical diagnoses. This may have affected the distribution of SREs if some diagnosis codes are more sensitive or specific than others. As noted above, this study used data from the MedStat commercial database, and the estimates reported herein may not be generalizable to Medicare or other elderly patients. Further, the MarketScan commercial database is geographically diverse but not entirely representative of the US population, and patients from the database may not be representative of all commercially insured patients in the United States or other settings. Approximately 13% of patients in the study sample were in HMO plans. As a consequence of capitation arrangements, the payment field for office visits for these patients may result in potential underestimation of outpatient SRE costs. The extent of this bias is likely to be small, however, as cancer patients are likely to receive treatment from oncologists rather than primary care physicians, and the former are less likely to be in capitated payment arrangements than the latter. Lastly, for some SRE episode categories (for example, inpatient and outpatient surgery to bone), the number of events was small and our estimates may lack precision.
Despite these limitations, this study has important implications. First, results of this study suggest that SREs are associated with high costs and hospitalizations among patients with prostate cancer and bone metastases, and that these costs may be greater than estimated previously for some events. This study also demonstrates the utility of EOC-based analyses for evaluating the costs of clinical events in retrospective studies using health insurance claims data.
